期刊文献+

Immunomodulatory and chemopreventive effects of resveratrol on the digestive system cancers

下载PDF
导出
摘要 Resveratrol(RSV),the primary polyphenol found in grapes,has been revealed to have anti-inflammatory properties by reducing the capacity of the peripheral blood mononuclear cells to produce pro-inflammatory cytokines,including IL-1β,IL-6,IL-1ra and TNFα.Considering the close association between chronic inflammation and cancer development,RSV’s immunomodulatory properties are one way by which the polyphenol may inhibit cancer initiation,proliferation,neovascularization,and migration.Resveratrol influences the generation of microtumor environment which is one of the key factors in cancer progress.In addition to immunomodulation,RSV inhibits cancer development by expressing anti-oxidant effects,causing cell cycle arrest,stimulating the function of certain enzymes,and activating cell signaling pathways.The end outcome is one of the various forms of cell death,including apoptosis,pyroptosis,necroptosis,and more,as it has been observed in vitro.RSV has been shown to act against cancer in practically every organ,while its effects on colon cancer have been documented more frequently.It is remarkable that longer-term clinical studies that may have established the potential for this natural substance to serve as a therapeutic adjuvant to traditional anti-cancer medications were not prompted by the encouraging outcomes seen with cancer cells treated with non-toxic doses of resveratrol.The current review aims to assess the recent findings about the immunological and anti-cancer characteristics of RSV,with a particular emphasis on cancers of the digestive tract,as a challenge for future clinical research that may contribute to the better prognosis of cancer.
出处 《Oncology Research》 SCIE 2024年第9期1389-1399,共11页 肿瘤学研究(英文)
  • 相关文献

参考文献6

二级参考文献47

  • 1Min-Yu Chung,Tae Gyu Lim,Ki Won Lee.Molecular mechanisms of chemopreventive phytochemicals against gastroenterological cancer development[J].World Journal of Gastroenterology,2013,19(7):984-993. 被引量:7
  • 2Nagata M. Inflammatory cells and oxygen radicals. Curr Drug Targets 2005, 4: 503-504.
  • 3Brummer E, Capilla J, Bythadka L, Stevens OA. Production of IL-6, in con?trast to other cyrokines and chemokines, in macrophage innate immune responses: effect of serum and fungal (Blastomyces) challenge. Cytokine 2007,39: 163-170.
  • 4Cole JE, Mitra AT, Monaco C. Treating atherosclerosis: the potential of Toll-like receptors as therapeutic targets. Expert Rev Cardiouasc Ther 2010,8: 1619-1635.
  • 5Deng Y, Yang Z, Gao Y, Xu H, Zheng B, Jiang M, Xu J, et al. Toll-like re?ceptor 4 mediates acute lung injury induced by high mobility group box-I. PLoS One 2013,8: e64375.
  • 6Kass OJ, Yu G, Loh KS, Savir A, Borczuk A, Kahloon R, Juan-Guardela B, et al. Cyrokine-like factor 1 gene expression is enriched in idiopathic pul?monary fibrosis and drives the accumulation of C04+ T cells in murine lungs: evidence for an anrifibroric role in bleomycin injury. Am J Pathol 2012, 180: 1963-1978.
  • 7Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005, 17: 1-14.
  • 8Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflamma?tion and cancer. Mol Cancer 2013, 12: 86.
  • 9Wang H, Yang H, Tracey KJ. Extracellular role ofHMGBl in inflammation and sepsis.J Intern Med 2004, 255: 320-331.
  • 10Kim S, Kim SY, Pribis JP, Lotze M, Mollen KP, Shapiro R, Loughran P, et al. Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14. Mol Med 2013, 19: 88-98.

共引文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部